Peptide Receptor Radionuclide Therapy with [
PRRT
[177Lu]Lu-DOTA-TATE
neuroendocrine neoplasms
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
24 Jan 2022
24 Jan 2022
Historique:
received:
10
12
2021
revised:
17
01
2022
accepted:
20
01
2022
entrez:
15
2
2022
pubmed:
16
2
2022
medline:
16
2
2022
Statut:
epublish
Résumé
This review article summarizes findings published in the last years on peptide receptor radionuclide therapy in GEP NENs, as well as potential future developments and directions. Unanswered questions remain, such as the following: Which is the correct dose and individual dosimetry? Which is the place for salvage PRRT-Lu? Whicht is the role of PRRT-Lu in the pediatric population? Which is the optimal sequencing of PRRT-Lu in advanced GEP NETs? Which is the place of PRRT-Lu in G3 NENs? These, and future developments such as inclusion new radiopharmaceuticals and combination therapy with different agents, such as radiosensitizers, will be discussed.
Identifiants
pubmed: 35158852
pii: cancers14030584
doi: 10.3390/cancers14030584
pmc: PMC8833790
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Eur J Nucl Med Mol Imaging. 2014 Feb;41(2):205-10
pubmed: 24030668
Endocr Relat Cancer. 2019 Aug;26(8):C7-C11
pubmed: 31200364
Neuroendocrinology. 2016;103(2):119-24
pubmed: 26784901
J Histochem Cytochem. 2019 Oct;67(10):735-743
pubmed: 31381461
Mod Pathol. 2017 Apr;30(4):587-598
pubmed: 28059098
J Clin Oncol. 2018 Sep 1;36(25):2578-2584
pubmed: 29878866
J Nucl Med. 2020 Feb;61(2):222-227
pubmed: 32015164
Cancer Res. 2005 Oct 15;65(20):9194-9
pubmed: 16230379
Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2106-19
pubmed: 25070685
J Clin Oncol. 2005 Apr 20;23(12):2754-62
pubmed: 15837990
EJNMMI Phys. 2018 Oct 15;5(1):25
pubmed: 30318563
Clin Gastroenterol Hepatol. 2019 Oct;17(11):2212-2217.e1
pubmed: 30580091
Cancer Biother Radiopharm. 2015 Aug;30(6):261-9
pubmed: 26181854
Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16436-41
pubmed: 17056720
Neuroendocrinology. 2016;103(2):153-71
pubmed: 26742109
Nucl Med Rev Cent East Eur. 2016;19(2):111-7
pubmed: 27479788
Br J Radiol. 2018 Nov;91(1091):20180041
pubmed: 29513039
Eur J Nucl Med Mol Imaging. 2011 Feb;38(2):302-11
pubmed: 21052661
J Clin Oncol. 2008 May 1;26(13):2124-30
pubmed: 18445841
Neoplasia. 2017 Dec;19(12):991-1002
pubmed: 29091800
Ann Oncol. 2015 Aug;26(8):1604-20
pubmed: 25646366
Clin Nucl Med. 2019 May;44(5):e329-e335
pubmed: 30932975
J Nucl Med. 2013 Jan;54(1):33-41
pubmed: 23223392
Oncologist. 2019 Dec;24(12):e1315-e1320
pubmed: 31332100
Eur J Nucl Med Mol Imaging. 2011 Dec;38(12):2125-35
pubmed: 21892623
Ann Oncol. 2020 Jul;31(7):844-860
pubmed: 32272208
Pharmaceutics. 2021 Jun 18;13(6):
pubmed: 34207408
J Nucl Med. 2006 Sep;47(9):1467-75
pubmed: 16954555
JAMA Oncol. 2017 Oct 1;3(10):1335-1342
pubmed: 28448665
J Nucl Med. 2017 Sep;58(Suppl 2):1S-2S
pubmed: 28864608
Eur J Nucl Med Mol Imaging. 2018 Feb;45(2):262-277
pubmed: 28894897
Clin Transl Oncol. 2019 Jan;21(1):55-63
pubmed: 30535553
Nucl Med Commun. 2021 Apr 1;42(4):451-458
pubmed: 33346603
Clin Cancer Res. 2017 Aug 15;23(16):4617-4624
pubmed: 28428192
Eur J Nucl Med Mol Imaging. 2015 Jul;42(8):1238-46
pubmed: 25808630
Sci Rep. 2020 Jun 23;10(1):10196
pubmed: 32576907
Eur J Nucl Med Mol Imaging. 2020 Apr;47(4):980-990
pubmed: 31912256
Eur J Nucl Med Mol Imaging. 2013 May;40(5):800-16
pubmed: 23389427
Oncotarget. 2016 May 19;9(19):14791-14802
pubmed: 29599907
Neuroendocrinology. 2016;103(2):172-85
pubmed: 26731013
Cancer Res. 2013 Jan 1;73(1):12-8
pubmed: 23149918
EJNMMI Res. 2014 May 30;4:21
pubmed: 24995150
Eur J Nucl Med. 2001 Sep;28(9):1319-25
pubmed: 11585290
Eur J Nucl Med Mol Imaging. 2010 Feb;37(2):212-25
pubmed: 19727718
Molecules. 2020 Sep 02;25(17):
pubmed: 32887456
Neuroendocrinology. 2017 Apr 13;105(3):295-309
pubmed: 28402980
J Nucl Med. 2016 Feb;57(2):260-5
pubmed: 26514177
BMC Cancer. 2019 Aug 8;19(1):788
pubmed: 31395036
Oncotarget. 2018 May 15;9(37):24693-24706
pubmed: 29872498
Neuroendocrinology. 2017 Feb 17;105(3):310-319
pubmed: 28222443
Eur J Nucl Med Mol Imaging. 2018 Jun;45(6):923-930
pubmed: 29387927
Br J Radiol. 2018 Nov;91(1091):20170172
pubmed: 30028180
J Nucl Med. 2010 Mar;51(3):383-90
pubmed: 20150247
Semin Nucl Med. 2016 May;46(3):225-38
pubmed: 27067503
Eur J Nucl Med Mol Imaging. 2008 Apr;35(4):743-8
pubmed: 18188559
J Nucl Med. 2015 Feb;56(2):177-82
pubmed: 25593115
Eur J Nucl Med Mol Imaging. 2017 Jul;44(7):1207-1214
pubmed: 28246882
J Nucl Med. 2011 Dec;52(12):1886-90
pubmed: 22068898
Cancer Biother Radiopharm. 2007 Jun;22(3):406-16
pubmed: 17651048
N Engl J Med. 2017 Jan 12;376(2):125-135
pubmed: 28076709
Neuroendocrinology. 2019;109(4):333-345
pubmed: 31167197
J Nucl Med. 2020 Nov;61(11):1544-1552
pubmed: 33037092
Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):704-717
pubmed: 30267116
J Immunother Cancer. 2020 Jul;8(2):
pubmed: 32616557
J Nucl Med. 2019 Mar;60(3):377-385
pubmed: 30115686
EJNMMI Res. 2015 Dec;5(1):62
pubmed: 26553049
Cancer Treat Rev. 2021 Feb;93:102141
pubmed: 33418096
Eur J Nucl Med Mol Imaging. 2015 Dec;42(13):1964-70
pubmed: 26253273
Q J Nucl Med Mol Imaging. 2010 Aug;54(4):411-28
pubmed: 20823809
BMC Cancer. 2017 Aug 8;17(1):528
pubmed: 28789624
J Drug Target. 2016;24(2):169-77
pubmed: 26211366
Pancreas. 2014 May;43(4):518-25
pubmed: 24632546
J Nucl Med. 2017 Feb;58(2):288-292
pubmed: 27688470
Theranostics. 2018 Nov 29;8(22):6088-6100
pubmed: 30613284
Endocr Relat Cancer. 2019 Feb 1;26(2):227-239
pubmed: 30540557
Theranostics. 2016 Jul 18;6(11):1821-32
pubmed: 27570553
Cancer Chemother Pharmacol. 2013 Mar;71(3):663-70
pubmed: 23370660
Nucl Med Commun. 2019 Dec;40(12):1195-1203
pubmed: 31658219
Ann Oncol. 2020 Nov;31(11):1476-1490
pubmed: 32861807
Clin Nucl Med. 2017 Nov;42(11):e457-e466
pubmed: 28872545
Neuroendocrinology. 2016;103(2):186-94
pubmed: 26731334
EJNMMI Res. 2020 Apr 25;10(1):41
pubmed: 32335736
Ann Nucl Med. 2020 Apr;34(4):244-253
pubmed: 32114682
Pediatr Blood Cancer. 2021 Jul;68(7):e29056
pubmed: 33844446
Glob Pediatr Health. 2019 Jul 22;6:2333794X19862712
pubmed: 31384627
Pharmacol Rev. 2018 Oct;70(4):763-835
pubmed: 30232095
Eur J Nucl Med Mol Imaging. 2014 Oct;41(10):1845-51
pubmed: 24615468
Eur J Nucl Med Mol Imaging. 2015 Dec;42(13):1955-63
pubmed: 26112388
Oncologist. 2007 Aug;12(8):942-51
pubmed: 17766653
Neuroendocrinology. 2013;97(4):347-54
pubmed: 23392072
Oncotarget. 2018 Feb 15;9(24):16932-16950
pubmed: 29682195
Endocr Relat Cancer. 2019 Feb 1;26(4):437-449
pubmed: 30730850